Our findings demonstrated the enhanced therapeutic effect of HDAC inhibitors by disrupting MES-like GBM cell-MDM interactions through LGALS3 inhibitors, providing a combination therapy capable of simultaneously blocking intrinsic tumour cell signalling and remodelling cancer cell mediated immunosuppression. Here, HDAC9 is linked to glioblastoma.